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1. Introduction  
Neurologists in the 19th century recognized that muscle weakness could be due to primary 
disorders of muscle or secondary to loss of neuromuscular integrity, as happens when 
peripheral nerves are cut or when motor neurons degenerate. Furthermore, it was observed 
that there are forms of motor neuron degeneration which selectively affect upper motor 
neurons or lower motor neurons. A combination of upper and lower motor neuron 
dysfunction was named amyotrophic lateral sclerosis (ALS) by Charcot and Joffroy (Ringel, 
et al 1993). Jean-Martin Charcot first characterized the disease in 1874, naming the illness 
Amyotrophic lateral sclerosis (ALS) (Swash, 2001).  In USA, ALS or Lou Gehrig's disease are 
terms used to describe all forms of the disease, whatever the combination of upper and 
lower motor neuron involvement (Ringel, et al 1993). ALS is now a term which classifies the 
most common form of the illness and is often used synonymously with MND (Swash, 2001). 
In the UK the umbrella term motor neuron disease (MND) is more common. MND is a 
disease of middle to late life with a mean age of onset of 58 years, (Ringel, et al 1993). 
Actually, motor neuron diseases (MND) are a group of degenerative disorders that 
selectively affect motor neurons in the brain and spinal cord. Two groups of motor neurons 
are involved, lower motor neurons located in ventral horns of the spinal cord and brainstem 
motor nuclei, and upper motor neurons located in the cerebral cortex together with 
pyramidal tracts in spinal cord. The term MND is a broad spectrum term including 
amyotrophic lateral sclerosis.  
2. Definitions and terminology of motor neuron disease (MND) 
MND is a group of incurable progressive neurodegenerative disorders in which degeneration 
involves upper and lower motor neurons in different body regions, resulting in progressive 
weakness of bulbar, limbs and respiratory musculature, in different combination. 
MND is an adult onset neurodegenerative disease which leads inexorably via weakness of 
limb, bulbar and respiratory muscles to death from respiratory failure three to five years 
later. (Allum and Shaw 2010). 
3. Epidemiology of motor neuron disease 
The prevalence of MND is 4-6 per 100,000 in most parts of the world, except the Western 
Pacific foci, (Leigh, 1991). However, its annual incidence is between 1.5 and 2/100,000 and 
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males are more commonly affected than females (1.4:1). The incidence increases with age 
with a mean age of onset of 63 years, (Ringel, et al 1993). It ranks as the third most common 
neurological degenerative disorder after Alzheimer's and Parkinson's disease (Talbot 2002). 
In Guam, the incidence of MND has fallen from 87/100,000 in 1962 to 5/100,000 in 1985, 
(Rodgers-Johanson, et al. 1986).  
Within the Caucasian population of Europe and North America, where most of the studies 
have been conducted, the lowest reported incidence of MND was 0.6 per 100.000 person –
years in Italy,(De Domenice, et al. 1988) and the highest reported was 2.4 per 100.000 person-
years in Finland(Murros and Fogelholm.1983). However, a lower incidence rate of 0.3/100,000 
person-years was reported among Asian population, in China, (Fong, et al. 1996). 
In the only well-conducted study of MND incidence among black African population, the 
incidence of MND was noted to be 0.9 per 100,000 person-years in Libya, (Radhakrishnan, et 
al. 1986). 
The incidence of MND is said to be increasing, but this is probably the result of improved 
diagnosis, better awareness of the disease and an aging population, (Leigh and Ray-
Chaudhuri.1994). The incidence increases after the age of 40 years, peaks in the late 60s and 
early 70s, and declines rapidly after that, (Logroscino, et al. 2008). 
4. Aetiology, pathology and pathogenesis of motor neuron disease 
MND is one of the complex and misunderstood diseases that health care professionals may 
encounter for various different reasons: (1) there are multiple different forms of the disease 
(Strong and Rosenfeld.2003), (2) the pathogenesis is not fully delineated (Wijesekera and 
Leigh.2009), (3) diagnosis can occur only by exclusion, (4) there exists only FDA approved 
medication, riluzole, for the treatment of ALS2 (Washington.2007), and despite this, (5) there 
is no cure for this disease. 
Environmental exposures during the Gulf war have been proposed as the explanation for an 
increased incidence of ALS among Gulf War veterans (Haley 2003, Horner et al, 2003). 
4.1 Neuropathological findings in MND 
Gross changes were frontotemporal atrophy, which was usually mild to moderate, neither 
circumscribed nor of a 'Knife-blade' type, and atrophy of the anterior roots in the 
cervicothoracic spinal cord, which was seen in cases with definite lower motor neuron 
involvement. Cortical atrophy was marked in the limbic system including the temporal 
pole, parahippocampus and amygdala but usually spared the hippocampus in typical ALS – 
Dementia (ALS-D) cases. (Yoshida 2004). 
Histological changes included neuronal loss and gliosis with sponginess in layers II and III 
of frontotemporal cortices with predominant involvement of the limbic system including the 
anterior cingulated gyrus, anterior temporal and insular lobes, parahippocampus, 
subiculum and amygdale in typical cases. (Yoshida 2004). 
The full pathogenesis of ALS is not well understood as it has not been fully elucidated by 
medical research. However, several key factors can be noted including: (1) Genetics, (2) 
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Excitotoxicity, (3) Oxidative stress, (4) Mitochondrial dysfunction, (5) Impaired axonal 
transport, (6) Neurofilament aggregation, (7) Protein aggregation, (8) Inflammatory 
dysfunction and contribution of non-neuronal cells, (9) Deficits of neurotrophic factors and 
dysfunction of signaling pathways, and (10) Apoptosis, (Wijesekera and Leigh.2009 and 
Shaw. 2005).  
4.2 Genetics 
Up to 90% of all ALS cases, occurs without family history, (sporadic ALS) and about 10% 
of cases are familial ALS (FALS). SALS is clinically indistinguishable from FALS, but the 
average age of onset in FALS is somewhat earlier, (Celveland and Rothstein (2001). 
Enteroviral infections and mutations of superoxide dismutase 1gene (SOD1) have been 
implicated in the pathogenesis of MND (oluwale et al 2001). About 25% of ALS cases, 
(Celveland and Rothstein (2001), and 2% of the sporadic cases, are linked to mutations in 
the gene encoding copper/zinc superoxide dismutase (SOD1). It is Known that there may 
be as many as six gene loci that code for the ALS phenotype, but only three have been 
identified. Several other mutations have also been documented to possibly take part in the 
pathogenesis of ALS, (Wijesekera and Leigh, 2009). Since the link between SOD1 and 
FALS was first established, >90 FALS-linked SOD1 mutations have been discovered, 
(Celveland and Rothstein (2001). Most of these mutations are point missense mutations, 
(Anderson, et al. 2003). Most of the genetics are transmitted via the autosomal dominant 
route, though some are autosomal recessive and others may be sex-linked, (Wijesekera 
and Leigh.2009). 
4.3 Excitotoxicity 
Excitotoxicity is a term used to signify the damage that occurs to neuronal cells that are 
characterized by overstimulated glutamate receptors, as glutamate is the major excitatory 
neurotransmitter in the human central nervous system (Riluzol monograph. 2011). As SOD1 
codes for the major reuptake protein of glutamate, a mutation limits the concentration levels 
of that reuptake protein, allowing an excessive amount of glutamate to be present in the 
neuronal synapse. It is also postulated that glutamatergic toxicity plays a direct role in the 
destruction of neuronal cells in patients with ALS.( Shaw. 2005). 
4.4 Oxidative stress  
Oxidative stress is of particular interest to researchers due to the fact that the SOD1 gene 
mutation that is known to cause ALS, normally codes for an anti-oxidant protein. (Riluzol 
momgraph. 2011) 
4.5 Mitochondrial dysfunction 
There are many new data which supports the theory that mitochondrial dysfunction plays 
an important role in the pathogenesis of ALS. Multiple cases of dysfunctional mitochondria 
have been noted in post-mortem analyses of ALS patients. (Wijesekera and Leigh.2009) 
Dysfunctional mitochondria have also been linked to the SOD1 gene mutation in mice 
models. (Shaw. 2005) 
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4.6 Impaired axonal transport 
The theory that axonal transport is a key to ALS pathogenesis stems from SOD1 transgenic 
mice models. Mice from these models often show slowed anterograde and retrograde axonal 
transport. Although no human ALS patient has presented with this problem, yet it is known 
to occur in several other neuromuscular disorders of the human body. (Wijesekera and 
Leigh.2009) 
4.7 Neurofilament aggregation 
Abnormal neuronal assembly, including accumulation of neurofilaments, are often seen in 
ALS patients. Neurofilaments can combine with a toxic form of peripherin, an intermediate 
filament protein, and become toxic to neurons even at modest concentration levels. This 
combination has been found in the spinal cord of ALS patients and not in controls. This 
evidence points to neurofilament aggregation as being a part of ALS pathogenesis. 
(Wijesekera and Leigh.2009) 
4.8 Protein aggregation 
Long debates as to whether protein aggregation take a part in disease pathogenesis have 
been occurred. It is possible that these inclusions may simply be innocent bystanders, or 
even beneficial to the cells. (Wijesekera and Leigh.2009) 
4.9 Inflammatory dysfunction and contribution of non-neuronal cells  
It has been recently discovered that SOD1 mutations alone are insufficient to cause ALS in 
transgenic mice, making the case that non-neuronal cells, as microglial and dendritic cells, 
may play a part in ALS pathogenesis (Shaw, 2005). ALS patients commonly experience 
activation of the non-neuronal microglial and dendritic cells. This activation has been shown 
to produce inflammatory cytokines such as interleukins and tumor necrosis factor (TNF). 
However, recent trials have yet to see success in utilizing immunomodulatory drug 
therapies to curve the progression of ALS. (Wijesekera and Leigh.2009). 
4.10 Deficits of neurotrophic factors and dysfunction of signaling pathways  
Lowered levels of neurotrophic factors have been noticed in post-mortem analysis of several 
ALS patients. In addition, three mutations in the Vascular Endothelial Growth Factors 
(VEGF) gene were thought to be associated with an increased risk for developing ALS. 
However, recently these finding have come under scrutiny due to an inability to replicate 
research results. (Wijesekera and Leigh.2009) 
4.11 Apoptosis  
Current research also skews towards examining if ALS motor neuron destruction occurs via 
a programmed cell death, or apoptosis. Several studies have shown that cell death due to 
ALS often occurs because of this programmed apoptosis, yet these findings are still being 
reviewed and discussed heavily. ( Shaw. 2005). 
 Motor Neuron Disease 
 
205 
5. Clinical presentation of motor neurone disease 
Dilemmas of symptoms and signs are described for diagnosis of MND and its subtypes. 
Motor symptoms of both upper and lower motor neuron dysfunction can occur in any 
muscle group, including limbs, and, or bulbar regions. Combinations of the previous motor 
symptoms is not characteristic for MND and can be observed in many diseases, known as 
"MND Mimic Disorders" such as, Kennedy's diseases, multifocal motor neuropathy, 
brainstem lesions (syrinx, stroke,………. etc) 
Meticulous evaluation by thorough history and examination by two or more specialists of 
neurology are required for diagnosis of MND. Special investigations are required for 
diagnosis of MND and differentiation from MND mimics. 
 
Preclinical stage Diagnosis stage Progression stage Terminal stage 
 Long duration 
(months or even 
years 
 Disease spread 
through motor 
system 
 Usually 
Asymptomatic 
 Selective involvement 
of motor neurons in 
the anterior horns of 
the spinal cord early 
and late in the disease 
(Swash et al. 1986) 
 corticospinal pathways 
in the cord are 
similarly, 
asymmetrically 
affected (Ingram and 
Swash 1987) 
 Onuf''s sacral nucleus 
(innervate anal and 
urinary sphincter 
muscles) are always 
spared (Schroder, and 
Reske Nelson 1984) 
 Ocular motor nuclei 
are also relatively 
resistant (Mulder 1982)
 weakness of one 
leg followed by 
other leg and 
patient will 
require a 
wheelchair to 
assist him 
 Swallowing 
Problems 
 Respiratory 
muscle weakness 
and dyspnea 
 All these 
symptoms are 
observed in 
different 
combinations 
according to 
different subtypes 
of MND 
 Respiratory 
insufficiency 
symptoms 
orthopnea, excessive 
daytime sleepiness, 
poor concentration, 
memory and appetite 
and signs of 
tachypnea, 
tachycardia, syncope 
and confusion, 
(Radunovic et al 
2007.) 
 Nursed and care for 
24 hours 
 Medication, Diet, 
Hygiene and special 
attention for 
respiration. 
Table 1. Stages of Motor Neuron Disease (MND) 
6. Bad prognostic factors for MND  
1. Late age of onset. 
2. Severe and early presentations of bulbar symptoms.  
3. Respiratory complications. 
The classical concept that MND only affects the motor system is obsolete. MND is 
considered to be a multisystem neurodegenerative disease. There is increasing clinical 
evidence for autonomic dysfunction (Baltadzhieva, et al 2006 and Takeda, et al, 1994), 
sensory abnormalities (Takeda et al, 1994) (Pugdahl et al, 2007) and ophthalmoplegia 
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(Takeda, et al, 1994) in MND. On the other hand, there are good pathological accounts of the 
involvement of sympathetic and parasympathetic neurons, (Takeda, et al, 1994), Onuf's 
nucleus (which innervates the pelvic floor sphincteric muscles), (Takeda, et al, 1994) 
peripheral sensory nerves, (Isaacs, et al. 2007) and oculomotor nuclei. (Takeda, et al, 1994). 
However, in practical terms, the presence of prominent ophthalmoplegia, sensory signs or 
sphincter dysfunction should raise doubts regarding the diagnosis of MND, unless there are 
a clear alternative explanation. Death usually results from ventilatory muscle weakness 
causing respiratory failure. 
7. Motor neuron disease presenting to non neurological specialists 
Respiratory: Progressive respiratory Failure 
Ear, nose, and throat: Dysphagia. 
Orthopaedics/ neurosurgery: Foot drop or other symptoms suggestive of compressive 
radiculopathy 
Elderly care: Difficulty walking. (Talbot 2002). 
 
 ALS PMA PLS PBP 
1. Age of onset 50-70 years  40 – 60 years  
2. Percent of 
Frequency 
(Leigh et al 
2003) 
60 – 70 % 10 % 1 % 20% 
3. Incidence 
(Strong and 
Rosenfeld, 2003)
1,2-1,8/100,000 ----- 
1/1000,000- 
Brugman and 
wokkle 2004 
----- 
4. Prevalence (van 
der, Graaff, 
2004) 
5-9/100,000 ----- 
10-20/1000,000-
Brugman and 
wokkle 2004 
----- 
5. Male to female 
Ratio ( Leigh et 
al 2003) 
3:2 3:4 
 
3:1 
(Talbot 2002) 
1:1 
6. Anatomical 
localization Cortical & spinal spinal cord 
Limb, Bulbar 
(Pseudo bulbar) 
Bulbar, 
Speech and 
limb 
7. Upper Motor 
Neuron 
manifestations 
Present Absent Present Absent 
8. Lower Motor 
Neuron 
manifestation 
Present 
Present in 
Limb muscles 
absent 
Present in 
bulbar 
muscles 
9. Cognitive 
impairment 
Present and some 
group of ALS 
without cognitive 
impairment 
Present 
Usually absent 
(Raaphorst et al 
2010) 
Absent 
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10. Bulbar 
symptoms 
Present Absent Present Promiment 
11. Mimic 
syndromes 
-Compressive 
myeloradiculopathy, 
-Paraneoplastic 
syndrome, 
-Encephalo-myelitis 
with anterion horn 
cell involvement 
-Inflammatory 
Myopathy 
-Multifocal motor 
neuropathy with 
conduction block
-Myasthenia 
Gravis 
-Toxic 
Neuropathies 
-Post polio 
Progressive 
muscular atrophy
-Primary 
progressive 
multiple sclerosis,  
-vit. B12 deficiency 
-Hereditay spastic  
Paraparesis,  
-Rarely small 
vessel 
cerebrovascular 
diseases 
-cervical 
Spondylotic 
myelopathy 
Posterior 
inferior 
cerebellar 
artery 
occlusion  
12. Emotional 
lability 
May be Present Present Prominent Absent 
13. Investigotions 
a. EMG&CV Positive- lower 
motor neuron 
manifestations 
Positive- lower 
motor neuron 
manifestations 
Normal 
Fibrillation 
and 
Positive 
sharp 
waves. 
b. MRI brain 
When Bulbar 
manifestations 
are isolated 
symptoms and 
signs 
Normal Normal Normal Normal 
c. MRI spinal cord 
All Limb onset 
without bulbar 
symptoms 
Normal ---- Normal ---- 
14. Prognosis 
Median 
Survival (Leigh 
et al 2003) 
3-4 years 
5 years, more 
long survivors 
(>10 years) 
20 years and More 2-3years 
Table 2. Clinical Subtypes of Motor Neuron Disease 
8. Cognitive function impairment in motor neuron disease 
Cognitive impairment is increasingly being recognized in MND. Subtle subclinical cognitive 
defects and frontal lobe dysfunction may be demonstrated in up to half of MND patients 
with detailed neuropsychological testing (Ringholz, et al. 2005). Several genetic mutations of 
MND have been identified in association with frontotemporal dementia and/or 
parkinsonism (Valdmanis and Rouleau. 2008). It is well recognized that MND is a 
multisystem disorder (Geser, et al, 2008) with compromise of regions beyond the motor 
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system, including cortical areas which are consistently involved in FTD. It comes as no 
surprise, therefore, that a proportion of patients presenting with MND manifest cognitive 
and/or behavioural changes which may be severe enough in some instances to reach criteria 
for frank FTD.(Irwin, et al, 2007). 
8.1 Amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) 
There is icreasing clinical, imaging and neurophysiological evidence that ALS represents a 
multisystem neurodegerative disease. Neurodegeneration is not restricted to motor neurons, 
but also includes parts of the brain other than the motor cortex, especially the preforntal 
and/or anterior temporal lobe, that contribute to the clinical syndrome. In some cases an 
evident dementia that resembles frontotemporal degeneration (FTD) was observed. It is 
now suggested that ALS and FTD are closely related conditions with overlapping clinical, 
pathological, radiological, and genetic characteristics. The presence of a frontal dementia in 
ALS has also crucial practical consequences for management of the patients, whose disorder 
requires critical life decisions for enteral nutrition and respiratory complications. (Zago, et 
al. 2010). 
8.2 The new classification of cognitive and behavioral disorder in ALS 
In 2009, Strong and colleagues articulated new guidelines to direct ongoing investigations  
of cognitive and behavioral syndromes in ALS (Strong et al., 2009). To define the 
 
Domain Test
Executive measure Wisconsin Card Sorting Test, Controlled Oral Word 
Association, FAS, D Words, Animal fluency, Written Word 
Fluency Design Fluency, California Card Sorting Test, Stroop 
Colour-Word Interference Test, Trail Making Test 
Memory/Learning Rey Auditory Verbal Learning Test, California Verbal 
Learning Test II, Warrington Recognition Memory Test, 
Wechsler Logical Memory and Visual Reproduction, Wechsler 
Paired Associate Learning. Kndrik Object Learning Test 
Attention/Concentration Verbal Serial Attention Test, Consonant trigrams Test, Symbol 
Digit Modit Modality Test, Paced Auditory Serial Addition 
Task, Digit Span 
Language Boston Naming Test, Graded Naming Test, Pyramid and palm 
Trees, Peabody Picture Vocabulary Test, British Picture 
Vocabulary Test, Test for the Reception of grammar 
Visual/Spatial Judgement of line Orientation, Benton Facial Recognition Test, 
Block Design, Motor-Free Visual Perception Test-Revised, 
Visual Object and Space Perception Battery 
Emotional/ Behavioral 
functioning 
Neuropsychiatric inventory, frontal Behavoural Inventory, 
Frontal Systems Behavioural Scale 
Table 3. Neuropsychological test for the evaluation of cognitive/behavioral impairment in 
ALS (modifed from Strong et al. 2009), with permission. 
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neuropsychological status of ALS patients a framework was based on four different axes. 
Axis I is based on the EL Escorial criteria proposed in 1998, that includes possible, probable, 
and definite ALS clinical subtypes. This multidimensional approach incorporates several 
criteria (Brooks et al, 2000). The novelty of the classification lies primarily in Axis II with the 
proposal of five categories which classify ALS patients along a continuum: (1) ALS patients 
cognitively and behaviorally intact: (2) ALS patients with mild cognitive impairments; (3) 
ALS patients with mild behavioral impairment; (4) ALS with a full-fledged fronto-temporal 
dementia; (5) ALS with other non FTD-forms of dementia. 
Axis III indicates the presence, in addition to frontotemporal impairments, of additional 
non-motoneuronal disease manifestations such as extrapyramidal signs, cerebellar 
degenerations, autonomic dysfunctions, sensory impairments, and ocular motility 
abnormalities. The absence of the above indicates a "pure form," while their presence defines 
"complicated forms" with additional pathological motor aspects. Axis IV, instead, provides 
the search for factors which could modify the course of the disease. Several disease 
modifiers have been reported in literature associated with longer survival, age at symptom 
onset (< 45 years), gender (male/sex), and site of the disease onset (bulbar or limb). 
9. Language 
Language deficits are occasionally found in the early stages of the disease. (Abrahams, et al. 
2004). 
The spectrum of language impairment in MND is wider than simply a problem in speech 
production due to dysarthria, but it is yet to be fully characterized. Reduced verbal output 
(adynamism) evolving into mutism has been reported, as well as echolalia. Perseverations, 
stereotypical expressions, (Bak and Hodges. 2004), true non-fluent aphasia with 
phonological and/or syntactic deficits and comprehension impairment have been reported 
in isolated cases. (Tsuchiya, et al. 2000) 
MND has also been associated with apraxia of speech, in which there is breakdown in 
articulatroy planning, producing slowed, effortful and dysprosodic speech with problems 
repeating multisyllabic words. Apraxia of speech is often accompanied by orobuccal apraxia 
but not necessarily with aphasia.(Duffy, et al ,2007). 
10. Memory 
It has been difficult to categorize the pattern of memory impairment, but current evidence 
suggests that memory problems are related to abnormalities in retrieval of the information 
secondary to frontal dysfunction. (Neary, et al. 2000). Memory problems involve primarily 
immediate recall, (Phukan. et al. 2007) but impairment of visual memory also has been 
implicated,(Kew, et al.1993) 
Frontal, temporal and thalamic hypoperfusion on SPECT has been shown to correlate with 
the severity of memory impairment. (Montovan, et al. 2003). 
Most strikingly, learning and memory were found to be significantly improved in patients 
in the later stages of the disease, (Lakerveld et al, 2008). 
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Definite ALS Upper and lower motor neuron signs in at least three body 
regions (upper limb, lower limb, bulbar, thoracic). 
Clinically probable ALS Upper and lower motor neuron signs in at least two 
regions, with some upper motor neuron signs necessarily 
rostoral to the lower motor neuron signs 
Clinically probable ALS: 
Laboratory-supported ALS 
Clinical signs of upper and lower motor neuron 
dysfunction in only one region, or when upper motor 
neuron signs alone are present in one region and lower 
motor neuron signs defined by electromyographic criteria 
are present in at least two limbs, with proper application of  
neuroimaging and clinical laboratory protocols to exclude 
other causes. 
Clinically possible ALS Clinical signs of upper and lower motor neuron 
dysfunction are together in only one region, or upper motor 
neuron signs are found alone in two or more regions, or 
lower motor neuron signs are found rostral to upper motor 
neuron signs and the diagnosis of clinically probable: 
laboratory-supported ALS cannot be proven by evidence 
on clinical grounds in conjunction with electrodiagnostic, 
neurophysiological, neuroimaging or clinical laboratory 
studies. Other diagnoses must have been excluded  
* (Brooks, 1994 and Brooks, et al. 2000) 
** Als: amyotrophic lateral sclerosis 
Table 4. Revised El Escorial criteria for the diagnosis of ALS.* 
11. Diagnostic criteria for motor neuron disease (amyotrophic lateral 
sclerosis, ALS) by** Leigh and Ray – Chaudhuri 1994 
The diagnosis of ALS requires the presence of: 
 LMN signs (including EMG features in clinically normal muscles) 
 UMN signs 
 Progression of the disorder 
11.1 Diagnostic categories 
 Definite ALS: UMN plus LMN signs in three regions** 
 Probable ALS: UMN plus LMN signs in two regions with UMN signs rostral to LMN 
signs 
 Possible ALS: UMN plus LMN signs in one region, or UMN signs in two or three 
regions, such as in monomelic ALS, progressive bulbar palsy, and primary lateral 
sclerosis 
 Suspected ALS: LMN signs in two or three regions, such as in progressive muscular 
atrophy, and other motor syndromes. 
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11.2 The diagnosis of ALS requires the absence of 
 Sensory signs 
 Sphincter disturbances 
 Visual disturbances 
 Autonomic dysfunction 
 Parkinson's disease 
 Alzheimer-type dementia 
 ALS "mimic" syndromes 
11.3 The diagnosis of ALS is supported by 
 Fasciculation in one or more regions 
 Neurogenic change in EMG studies 
 Normal motor and sensory nerve conduction (distal motor latencies may be increased) 
 Absence of conduction block   
Regions are defined as follows: brainstem, brachial, thorax and trunk, crural. UMN= Upper 
motor neuron; LMN= lower motor neuron.          
12. Management of motor neuron disease (MND) 
12.1 Investigations 
There are no specific investigations for MND. Till now there are no specific biochemical or 
pathological markers of MND. The aim of Elctrophysiological, Imaging and laboratory 
investigations is to exclude MND mimics and/ or to support clinical signs presented by the 
patients. 
Allum and Shaw (2010) clarified that investigations are important adjuncts to the clinical 
diagnosis of MND. Properly used they can provide supportive evidence of the clinical 
findings and help delineate the extent of disease. Investigations are also important to 
identify benign or treatable MND mimics. 
12.2 Treatment plan of motor neuron disease 
Although MND is still incurable disease up till now, in the last two decades MND 
management has evolved rapidly. Symptomatic treatment of MND still had the upper hand 
of management plan, especially for respiratory and bulbar complications. A team of work 
including neurologist, highly qualified nurses, ICU specialist in respiratory complications, 
psychologist, dietition, physiotherapy and speech therapist must be involved for 
management plan and follow up of MND patients, table (5). 
Thus treatment strategy of MND was aimed towards; 
1. Delay Progression of the disease and prevent further loss of motor neurons especially in 
the early stage of the disease  
2. Symptomatomatic treatment to alleviate symptoms of the disease aiming to maintain 
quality of life 
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Types of investigatory Tools Aim Findings 
I- Electrophysiology 
 Electromyography Identification of LMN loss 
help in diagnosis of ALS by 
establishing the Presence of 
subclinical LMN 
involvement  (Eisen and 
Swash. 2001)  
 Active denervation (positive 
sharp waves, fibrillation 
potentials, Fasciculation 
Potentials) 
 Chronic denervation 
evidenced by large motor unit 
potentials  (Allum and Shaw 
2010) 
 Single fibre EMG, macro 
EMG and central motor 
conduction using 
magnatic stimulation 
Reflect early reinnervation 
and collateral sprouting 
and may provide evidence 
of A.H.C. damage in 
normal muscles (Leigh Ray 
– chaudhuri 1994) 
Abnormal Jitter and blocking of 
neuromuscular trans -mission 
(Leig Ray – chaudhuri 1994) 
Nerve conduction studies 
Motor conduction Velocity To exclude disorders that 
mimic ALS 
 Normal in early stages of ALS. 
 In advanced disease the 
compound muscle action 
potential amplitude 
becomes reduced, indicating 
denervation    (Daube. 2000) 
Sensory conduction velocity Differentiating ALS From 
demyelinating 
neuropathies  (Eisen. 2001)
 Typically normal 
 Abnormal SCV should raise 
suspicion of an alternative 
diagnosis   (Eisen. 2001) 
II-Imaging 
 MRI spine for Limb onset 
ALS without bulbar 
manifestation 
To exclude cord and root 
compression 
Normal 
 MRI brain for ALS 
presented by bulbar 
manifestation 
To exclude infiltrative 
lesion of tongue and 
pharynx (Turner, et al, 
2009) 
Normal 
III- laboratory 
investigations 
 Routine investigations 
(complete blood count, 
liver, kidney and thyroid 
function tests, Blood sugar 
curve electrolyte, calcium, 
CK----- etc    
 
To exclude MND minics as
- Thyrotoxicosis 
- lymphomas 
- Paraneoplastic syndrome 
- Diabetic amyotrophy. 
 
According to diagnosed 
neurological disorders 
Table 5. Investigatory Tools for MND 
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Neurologist Diagnosis, disclosure of diagnosis, treatment and symptom 
management, initation of respiratory and nutritional 
interventions, unbiased information regarding research 
developments  
Family Doctor Symptom control, drug monitoring, liaison with other teams 
ALS Specialist Nurse Liaison with medical team and coordination of care, home visits, 
practical advice regarding accessing support services, patient 
advocacy 
Speech & Language 
Therapist 
Evaluation and monitoring of dysphagia and aspiration, speech 
therapy and counseling regarding communication devices 
Occupational Therapist Optimization of the patient's environment. Advice regarding 
safety awareness, adaptive and splinting devices, activity 
modification, driving, energy conservation, home modification 
Dietitian/Nutritionist  Evaluation of nutritional status and the need for tube feeding, 
management of dysphagia, management of enteral feeding 
Physiotherapist  Evaluation of muscle strength and function, advice regarding 
walking aids and orthoses, safety awareness 
Social Worker Advice and control, pain management, maintenance of quality of 
life, preservation of dignity 
Psychiatry and 
Neuropsychology 
Evaluation and management of cognitive impairment/dementia, 
adjustment disorders, anxiety and depression  
Respiratory Physician Assessment of respiratory dysfunction, initiation of non-invasive 
ventilation 
* (phukan and Hardiman, 2009) 
Table 6. Roles of the multidisciplinary team* with permission 
12.3 Different types of treatment  
1. pharmacological  
2. symptomatic and  
3. treatment of complications 
12.3.1 Pharmacological treatment 
Riluzole (2-amino-6-(trifluoromethoxy) benzothiazole, RP 54274) is the only drug licensed to 
treat ALS. Although the drug reduces glutamate-induced excitotoxicity, its précis 
mechanism in ALS is unknown. A Cochrane Library meta-analysis (including three double-
blind randomized placebo controlled trials by (Miller, 2002) suggests that riluzole provides a 
9% gain in the probability of surviving one year and adds approximately 2 months to 
patient survival.  
Riluzole, exerts the following pharmacologic effects: 
 An inhibitory effect on glutamate release. 
 Inactivation of Voltage – dependent sodium channels. 
 Ability to interfere with intracellular events that follow transmitter binding at excitatory 
amino acid receptor (Riluzole monograph 2011). 
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 Dosage 50mg twice daily 
 Side Effects Nausea and vomiting, Asthenia, somnolence Headache, dizziness, and 
vertigo 
 Serious Adverse Effects 
 Elevation in liver transaminases. Regular monitoring of liver function is advised 
(every month for 3 months, every 3 months for a further nine months then annually 
thereafter). 
 Rare cases of neutropenia have been reported. White cell count must be checked in 
the case of febrile illness 
Contraindications-Renal and hepatic impairment Pregnancy and breast-feeding 
(Brockington and Shaw, 2003) 
12.3.2 Symptomatic treatment 
 
Symptom Cause Drugs Other treatment 
Cramps Changes in  motor 
function 
Carbamazepine Phenytion 
Magnesium (Miller, et al, 1999; 
Andersen, et al, 2005) 
Physiotherapy 
Physical exercise 
Massage 
Hydrotherapy (Miller, 
et al, 1999; Andersen, 
et al, 2005) 
Spasticity Corticospinal tract 
damage 
Baclofen Tizanidine 
Dantrolene Botulinum toxin 
type A (Wnterholler et al,2002 ; 
Restivo et al, 2002) 
Physiotherapy (Millul 
et al, 2005) 
Hydrotherapy 
Cryotherapy 
Exessive watery
Saliva 
Bulbar weakness  Atropine Hyoscine 
hydrobromide (Miller, et al, 
1999; Andersen, et al, 2005) 
Amitriptyline (Bradley et al, 
2001) 
Home suction device 
Nebulisation 
(Andersen, et al, 2005) 
injections of 
botulinum toxin into 
parotid glands (Giess 
et al, 2000/ 
Winterholler et al, 
2001) irradiation of 
the salivary glands 
(Iannaccone et al, 
1996;  Stalpers and 
Moser, 2002) 
Persistent saliva 
and bronchial 
secretions 
-Bulbar weakness 
- Respiratory 
complications 
Carbocisteine Propranolol   
Metoprolol (Newall, et al, 
1996) 
Home suction device 
hydrobromide 
(Miller, et al, 
1999/Andersen, et al, 
2005) Reduced intake 
of diary products, 
alcohol, and caffeine. 
 Motor Neuron Disease 
 
215 
Excessive or 
violent yawning
Corticospinal tract 
damage 
(pseudobulbar 
syndrome) 
 
Baclofen  
Laryngospasm Pharyngeal 
sensitivity 
Lorazepam Reassurance 
Pain Immobility, 
stiffness 
- Simple analgesics - Non-
steroidal anti-inflammatory 
drugs 
-  Opioids 
Comfort (seating, 
sleeping, day and 
night care) 
Emotional 
lability 
Pseudobulbar 
syndrome 
Tricyclic antidepressant 
Selective serotonin-reuptake 
inhibitors (Iannaccone and 
Ferini, 1996) Levodopa  
Dextrometorphan and 
quinidien (Brooks, et al, 2004) 
 
Communication 
difficulties 
  Speaking techniques 
(Murphy, 2004) 
Voice amplifiers 
Brain-computer 
interfaces (Kübler et 
al, 2005) 
Constipation Immobility; 
opiates, 
Dehydration 
Lactulose  
Senna 
Hydration Increased 
fiber intake 
Depression - Hopelessness;  
- Inability to 
communicate; and 
frustration 
Amitriptyline Citalopram Psychological support 
counseling 
Insomnia Discomfort, pain, 
depression; 
(consider 
respiratory 
insufficiency) 
Amitriptyline  
Zolpidem 
Comfort, analgesia 
Anxiety Many Factors - Lorazepam 
- Midazolam 
- Diazepam 
suppositories 
Psychological 
support, counseling 
Fatigue - Muscle weakness
- Anxiety 
- Depression 
 Modafinil (Bradly et 
al 2001) 
Table 7. Symptomatic treatment of Motor Neuron Disease. Modified From Radunovic et al 
2007 and leigh et al 2003 
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12.3.3 Treatment of complication 
a. Respiratory complications 
Respiratory impairment is common in MND and may develop because of respiratory 
muscle weakness, impaired bulbar function causing aspiration or obstructive sleep apnea, or 
defects in central control. Dyspnea may be due to infection, pulmonary embolus, or airway 
obstruction from mucous plug or inhaled pharyngeal contents. (Howard and Wiles,1989). 
Symptoms of respiratory insufficiency may be subtle and develop insidiously. Patients may 
report dyspnea, orthopnea, sleep fragmentation due to hypoventilation, morning headaches, 
daytime somnolence and fatigue, poor concentration/memory and nocturia. Others may be 
asymptomatic. Respiratory muscle weakness is an in dependent predictor of quality of 
life.(Bourke, et al, 2001) and respiratory failure is the most common cause of death in ALS 
patients. Assessment of respiratory insufficiency includes history, physical examination, 
rarly morning arterial blood gas, and overnight pulse oximetry. 
Nocturnal hypoventilation may present as daytime hypersomnolence, lethargy, morning 
headaches, poor concentration, depression, anxiety, and irritability, while obstructive sleep 
apnea is characterized by snoring and restless sleep with abnormal movements. (Howard 
and orrell 2002). 
Types of mechanical ventilation 
There are several types of ventilatory aids. These are broadly classified in terms of invasive 
versus noninvasive.  
As its name suggests, invasive techniques require an endotracheal tube or more commonly a 
tracheostomy. For patients in advanced respiratory failure (ie, no respiratory muscle 
function), invasive ventilators can assume complete control of ventilation. (Simonds. 2003). 
Non- invasive ventilatory aids can be divided into two groups, negative or positive pressure 
ventilators. Negative pressure is exerted to the chest or abdominal wall mechanically to 
assist inspiration. Positive pressure devices can be set to deliver variable inspiratory and 
expiratory pressures, triggered by spontaneous effort (Simonds. 2003). 
b. Management of Dysphagia  
Management of Dysphagia includes modification of food and fluid consistency, postural 
advice (e.g. chin tuck: flexing the neck forward on swallowing to protect the airway), and 
parenteral feeding. 
A percutaneous endoscopic gastrostomy (PEG) placement is indicated for those who have 
symptomatic dysphagia or significant weight loss. (Miller, et al. 2002). Patients and their 
families should be suitably counseled regarding the benefits and risks of the procedure. 
13. Conclusion 
Motor neuron disease is of the most common neurodegenerative disorders of unknown 
etiology, and had no specific treatment. ALS is the commonest type, and in most literatures 
is used as a synonym for motor neuron disease. Diagnosis is still clinical, mainly, and the 
investigatory tools have a definite role for diagnosis of other motor neuron mimics. Once 
motor neuron disease is diagnosed, the prognosis is usually bad, especially when bulbar, 
and respiratory complications are evident. 
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